Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 11, 2012, Pages 1654-1658

  Hellerstein, Michael ^a   Xu, Yongxian ^a   Marino, Tracie ^a   Lu, Shan ^b   Yi, Hong ^c   Wright, Elizabeth R ^d   Robinson, Harriet L ^a  

^a Research and Development   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c EMORY UNIVERSITY   (United States)

^d CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

DNA vaccine; GEO D03 DNA vaccine; GM CSF adjuvant; HIV vaccine; HIV virus like particles

Indexed keywords

DNA VACCINE; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MESSENGER RNA; POL PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VPU PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTECTION; PROTEIN EXPRESSION; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS LIKE AGENT;

DNA VACCINE; GEO-D03 DNA VACCINE; GM-CSF ADJUVANT; HIV VACCINE; HIV VIRUS-LIKE PARTICLES;

ANIMALS; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV-1; HUMANS; VACCINES, DNA;

EID: 84869848516     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21978     Document Type: Review

References (19)

1. Mast E, Mahoney F, Kane M, Margolis H. Hepatitis b vaccine. Vaccines 2004:Chapter 16, Philadelphia, PA, W.B. Saunders Co.
2. Schiller JT, Lowy DR. Human papillomavirus vaccine for cervical cancer prevention. Vaccines 2004; Chapter 45, Philadelphia, PA, W.B. Saunders Co.
3. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318.
4. Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 2011; 204:164-73; PMID:21628671; http://dx.doi.org/10. 1093/infdis/jir199.
5. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al.; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203:610-9; PMID:21282192; http://dx.doi.org/10.1093/infdis/ jiq105.
6. Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, et al. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses 2004a; 20:1335-47; PMID:15650426; http://dx.doi.org/10. 1089/aid.2004.20.1335.
7. Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, et al. Multiprotein HIV-1 clade b DNA/MVA vaccine: construction, safety and immunogenicity. AIDS Res Hum Retro 2004b; 20:654-65; http://dx.doi.org/10.1089/ 0889222041217419.
8. Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol 1993; 67:6365-78; PMID:8411338.
9. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001; 1:209-19; PMID:11905830; http://dx.doi.org/10.1038/35105075.
10. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002; 13:185-93; PMID:11900993; http://dx.doi.org/10.1016/S1359-6101(01)00034-X.
11. Lai L, Kwa SF, Kozlowski PA, Montefiori DC, Nolen TL, Hudgens MG, et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012; 30:1737-45; PMID:22178526; http://dx.doi.org/10.1016/j. vaccine.2011.12.026.
12. Miller MA, Mietzner TA, Cloyd MW, Robey WG, Montelaro RC. Identification of a calmodulin-binding and inhibitory peptide domain in the HIV-1 transmembrane glycoprotein. AIDS Res Hum Retroviruses 1993; 9:1057-66; PMID:8312049; http://dx.doi.org/10.1089/aid.1993.9.1057.
13. Wyatt LS, Belyakov IM, Earl PL, Berzofsky JA, Moss B. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 2008; 372:260-72; PMID:18048074; http://dx.doi.org/10.1016/j.virol.2007.10.033.
14. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995; 2:129-35; PMID:7895169; http://dx.doi.org/10.1016/ S1074-7613(95)80001-8.
15. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43; PMID:8097319; http://dx.doi.org/10.1073/pnas.90.8.3539.
16. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64:6337-43; PMID:15342423; http://dx.doi.org/10.1158/0008-5472.CAN-04- 0757.
17. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colonystimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25:2546-53; PMID:17577033; http://dx.doi.org/10.1200/JCO.2006.08.5829.
18. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007; 18:226-32; PMID:17116643; http://dx.doi.org/10.1093/ annonc/mdl158.
19. Schell JB, Bahl K, Rose NF, Buonocore L, Hunter M, Marx PA, et al. Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody. Vaccine 2012; 30:4233-9; PMID:22537983; http://dx.doi.org/10.1016/j. vaccine.2012.04.046.